TG Therapeutics to Participate in the Cantor Global Healthcare Conference
TG Therapeutics (NASDAQ:TGTX) announced its participation in the upcoming Cantor Global Healthcare Conference in New York, NY from September 3-5, 2025. Michael S. Weiss, the company's Chairman and CEO, will engage in a fireside chat on Wednesday, September 3, 2025, at 10:20am ET.
Investors can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website.
TG Therapeutics (NASDAQ:TGTX) ha annunciato la sua partecipazione alla Cantor Global Healthcare Conference a New York, NY, dal 3 al 5 settembre 2025. Michael S. Weiss, Presidente e CEO dell'azienda, prenderà parte a una fireside chat mercoledì 3 settembre 2025 alle 10:20 ET.
Gli investitori potranno seguire la presentazione in diretta streaming dalla pagina Events nella sezione Investors & Media del sito web di TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) anunció su participación en la Cantor Global Healthcare Conference en Nueva York, NY, del 3 al 5 de septiembre de 2025. Michael S. Weiss, presidente y CEO de la compañía, participará en una charla fireside el miércoles 3 de septiembre de 2025 a las 10:20 ET.
Los inversores podrán acceder a la transmisión en vivo de la presentación desde la página Events, en la sección Investors & Media del sitio web de TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX)는 2025년 9월 3일부터 5일까지 뉴욕(NY)에서 열리는 Cantor Global Healthcare Conference에 참가한다고 발표했습니다. 회사의 회장이자 CEO인 Michael S. Weiss가 2025년 9월 3일 수요일 오전 10:20 ET에 파이어사이드 채팅에 참여합니다.
투자자는 TG Therapeutics 웹사이트의 Investors & Media 섹션에 있는 Events 페이지를 통해 발표를 실시간 웹캐스트로 시청할 수 있습니다.
TG Therapeutics (NASDAQ:TGTX) a annoncé sa participation à la Cantor Global Healthcare Conference à New York, NY, du 3 au 5 septembre 2025. Michael S. Weiss, président et CEO de la société, prendra part à une discussion informelle (fireside chat) le mercredi 3 septembre 2025 à 10h20 ET.
Les investisseurs pourront suivre la présentation en webdiffusion en direct via la page Events de la section Investors & Media du site de TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) gab bekannt, dass das Unternehmen an der Cantor Global Healthcare Conference in New York, NY, vom 3. bis 5. September 2025 teilnehmen wird. Michael S. Weiss, Chairman und CEO, wird an einer Fireside-Chat-Sitzung am Mittwoch, den 3. September 2025, um 10:20 ET teilnehmen.
Investoren können die Präsentation per Live-Webcast über die Events-Seite im Bereich Investors & Media auf der Website von TG Therapeutics verfolgen.
- None.
- None.
Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 - 5, 2025. The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) in Europe, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, Swissmedic in Switzerland, and Australia’s Therapeutic Goods Administration (TGA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) presenting at the Cantor Global Healthcare Conference 2025?
Who will represent TG Therapeutics at the Cantor Global Healthcare Conference?
Where can I watch TG Therapeutics' presentation at the Cantor conference?
Where is the Cantor Global Healthcare Conference 2025 being held?
